Use of CMV Negative Blood Components

Applicability This document applies to all AHS Laboratory Services and laboratories administered by Covenant Health.

Purpose This policy provides direction for the processes and procedures to effectively aid in the selection of CMV negative cellular blood components for appropriate patients in Alberta.

Background CMV safe (leukoreduced) and CMV IgG seronegative products are considered equivalent, except for the purpose of intrauterine transfusion. Canadian Blood Services maintains a small inventory of CMV IgG seronegative red cells for the sole purpose of intrauterine transfusion.

Policy *Orders for CMV negative blood components that fall outside of the indication listed in the table below will be assessed by a Pathologist/Transfusion Medical Director on a case by case basis.*

Patient Types	CMV Negative Blood Component Required
Fetus/Neonate for intrauterine transfusion or exchange transfusion	Yes

Responsibility

Transfusion Medicine Network is responsible for:
- reviewing this policy at minimum every 2 years and revising as necessary.

Laboratory Directors, Managers, and Supervisors are responsible for:
- ensuring that the transfusion service complies with the policy requirements for the provision of CMV negative units as outlined above.
- ensuring staff are familiar with the policy and procedures surrounding the use of CMV negative blood components.
- monitoring CMV negative blood components use for appropriateness.

Zone Clinical Department Heads are responsible for:
- familiarity with this policy on the use of CMV negative blood components.
- communicating with and educating clinical colleagues on the appropriate use of CMV negative blood components.

Laboratory Personnel are responsible for:
- familiarity with this policy on the use of CMV negative blood components.
- following local procedures and processes for orders that fall within this policy and for orders that are outside of this policy.
- appropriately recording blood component requirements when notified by physician and patient care givers.

Physician and patient care units (clinical staff) are responsible for:

- notifying the Transfusion Service of the requirement for CMV negative blood components
- notifying the Transfusion Service when CMV negative blood components are no longer required.

Reference

National Advisory Committee on Blood and Blood Products , CMV Statement dated Feb. 14, 2017

Determining Patients' Blood Component and Product Eligibility, CLS policy TM01- 3.2.2

2 22 Anti-CMV Negative Blood Products: Criteria For, Edmonton zone RTMBPS00222UAR

Canadian Society for Transfusion Medicine, Standards for Hospital Transfusion Services